D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations-Reference-Cited by-同舟云学术

D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations

Published:2017-07-31 Issue:10 Volume:96 Page:1641-1652
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Yui Shunsuke,Kurosawa Saiko,Yamaguchi Hiroki^ORCID,Kanamori Heiwa,Ueki Toshimitsu,Uoshima Nobuhiko,Mizuno Ishikazu,Shono Katsuhiro,Usuki Kensuke,Chiba Shigeru,Nakamura Yukinori,Yanada Masamitsu,Kanda Junya,Tajika Kenji,Gomi Seiji,Fukunaga Keiko,Wakita Satoshi,Ryotokuji Takeshi,Fukuda Takahiro,Inokuchi Koiti

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/article/10.1007/s00277-017-3074-y/fulltext.html

Reference34 articles.

1. Slovak ML, Kopecky KJ, Cassileth PA et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075–4083

2. Byrd JC, Mrozek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336

3. Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354–365

4. Dohner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424–447

5. Wakita S, Yamaguchi H, Miyake K et al (2011) Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 25:1423–1432

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter retrospective comparison between systemic mastocytosis with t(8;21) AML and KIT mutant t(8;21) AML;Blood Advances;2024-02-15

2. KIT‐mutated pediatric core‐binding factor systemic mastocytosis‐acute myeloid leukemia treated with avapritinib and decitabine;Pediatric Blood & Cancer;2024-01-30

3. Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer;Frontiers in Oncology;2024-01-12

4. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1;Pediatric Blood & Cancer;2023-11-28

5. Management of Advanced Systemic Mastocytosis and Associated Myeloid Neoplasms;Immunology and Allergy Clinics of North America;2023-11